Keryx Biopharmaceuticals Inc. KERX is a Boston-based biopharmaceutical company working in the field of renal diseases. The company’s only marketed product, Auryxia (ferric citrate) was approved in the ...

Akebia Therapeutics and Keryx Biopharmaceuticals announced today that they have signed an agreement to merge. Here are the details that investors need to know: This deal will be an all-stock ...

The biotech industry is rife with small companies that spend millions developing new drugs that may or may not get the green light from the Food and Drug Administration. Many face costly setbacks, ...

Keryx is hoping to get approval this year for a second indication to treat iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease. - here’s the release Related ...

NEW YORK (AP) -- Shares of Keryx Biopharmaceuticals Inc. more than doubled in value this week even after a steep drop Friday as Wall Street responded enthusiastically to clinical trial data for ...

Small cap biotech Keryx Pharmaceuticals' newly launched drug Auryxia looks like a clinical winner, yet the stock has been hit hard recently. Here are 5 reasons why Keryx could be a buy today. By Brian ...

Keryx Biopharmaceuticals (KERX +0.00%) is defying gravity. The company announced a share offering of $55 million after the market closed on Tuesday, yet shares are still up more than 12% in early ...

The most recent short interest data has been released by the NASDAQ for the 04/30/2014 settlement date, which shows a 2,194,388 share increase in total short interest for Keryx Biopharmaceuticals Inc.

With the Nasdaq Biotechnology Index up 65% since the start of the year, it's clear that the biotech sector performed extraordinarily well in 2013-but which stocks were the biggest winners? Several ...